ArticleClinics (Sao Paulo, Brazil)2026
Predictors of secondary cardiovascular events in older adults with community-acquired pneumonia: a prospective observational study.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlder adults hospitalized with Community-Acquired Pneumonia (CAP) frequently experience early secondary cardiovascular events. The authors quantified risk factors and the incremental value of frailty and cardiac biomarkers beyond the Pneumonia Severity Index (PSI).
methodsThe authors ran a single-center, prospective cohort of adults ≥65-years with CAP admitted between January and December 2024. The primary endpoint was any in-hospital SCE (acute heart failure, MI/ACS per Fourth Universal Definition, new atrial fibrillation/flutter, ischemic stroke/TIA, or cardiovascular death). Prespecified predictors were prior cardiovascular disease, PSI, Clinical Frailty Scale (CFS), High-Sensitivity Troponin (hs-cTn), and NT-proBNP. Penalized multivariable logistic regression estimated adjusted odds ratios, 30- and 90-day outcomes were used to cause-specific Cox and Fine-Gray models.
resultsAmong 172 patients (median age 77; 46% women), in-hospital SCEs occurred in 27.9% patients (48 out of 172 patients with 65 total component events; 95% CI 21.7-35.0), and 68.8% occurred within 72 h. Specifically, heart failure was 18.0%, new atrial fibrillation was 9.9%, MI was 5.8%, and cardiovascular death was 2.9%. In multivariable analysis, CFS ≥ 5 (Aor = 2.07, 95% CI 1.03-4.17), abnormal hs-cTn (aOR = 2.52, 1.25-5.06), and NT-proBNP per doubling (aOR = 1.38, 1.12-1.71) independently predicted SCEs. Discrimination improved from AUC 0.68 (PSI) to 0.73 with CFS and 0.79 with biomarkers (optimism-corrected 0.77), with NRI +0.18 and decision-curve net benefit at 10%-25% thresholds. Cumulative SCE incidence was 33.7% at 30-days and 37.8% at 90-days. Fine-Gray results were consistent.
conclusionsSCEs were common and occurred early after admission. Adding frailty and cardiac biomarkers to PSI improved risk stratification and may help high-risk patients receive closer monitoring. External validation is needed before its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.